Skip to main content
رجوع
LGND logo

Ligand Pharmaceuticals Incorporated

جودة البيانات: 100%
LGND
NASDAQ Healthcare Biotechnology
KWD 201.66
▲ KWD 1.30 (0.65%)
القيمة السوقية: 4.02B
نطاق اليوم
KWD 195.45 KWD 202.07
نطاق 52 أسبوعًا
KWD 93.58 KWD 227.92
حجم التداول
201,692
متوسط 50 يوم / 200 يوم
KWD 197.85 / KWD 172.55
الإغلاق السابق
KWD 200.36

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 32.3 0.3
P/B 4.0 2.9
ROE % 13.5 3.7
Net Margin % 46.4 3.8
Rev Growth 5Y % 2.6 10.0
D/E 0.4 0.2

السعر المستهدف للمحللين

Hold
KWD 248.000 +23.0%
Low: KWD 230.000 High: KWD 275.000
مكرر الربحية المستقبلي
23.2
ربحية السهم المستقبلية
KWD 8.626
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
270 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 14.510
KWD 13.648 – KWD 15.620
510 M 1
FY2029 KWD 11.250
KWD 10.581 – KWD 12.111
420 M 1
FY2028 KWD 10.305
KWD 8.993 – KWD 11.618
370 M 2

النقاط الرئيسية

Revenue grew 2.64% annually over 5 years — modest growth
ROE of 13.47% — decent returns on equity
Net margin of 46.42% shows strong profitability
Debt/Equity of 0.44 — conservative balance sheet
Generating 48.91M in free cash flow
P/E of 32.31 — premium valuation

النمو

Revenue Growth (5Y)
2.64%
Revenue (1Y)60.40%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
13.47%
ROIC2.41%
Net Margin46.42%
Op. Margin17.61%

الأمان

Debt / Equity
0.44
Current Ratio22.23
Interest Coverage0.00

التقييم

P/E Ratio
32.31
P/B Ratio3.95
EV/EBITDA91.06
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 60.40% Revenue Growth (3Y) 42.88%
Earnings Growth (1Y) N/A Earnings Growth (3Y) 54.48%
Revenue Growth (5Y) 2.64% Earnings Growth (5Y) 21.48%
Profitability
Revenue (TTM) 268.09M Net Income (TTM) 124.45M
ROE 13.47% ROA 7.97%
Gross Margin 97.54% Operating Margin 17.61%
Net Margin 46.42% Free Cash Flow (TTM) 48.91M
ROIC 2.41% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.44 Current Ratio 22.23
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio 32.31 P/B Ratio 3.95
P/S Ratio 15.00 PEG Ratio -0.01
EV/EBITDA 91.06 Dividend Yield 0.00%
Market Cap 4.02B Enterprise Value 4.30B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 268.09M 167.13M 131.31M 196.25M 241.54M
Net Income 124.45M -4.03M 52.15M -33.36M 57.14M
EPS (Diluted) 6.13 -0.22 2.94 -1.98 3.34
Gross Profit 261.50M 156.06M 96.27M 143.42M 179.37M
Operating Income 47.20M -22.61M 11.94M 3.04M 103.85M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.56B 941.77M 787.22M 762.67M 1.30B
Total Liabilities 543.43M 111.34M 86.30M 165.18M 476.43M
Shareholders' Equity 1.02B 830.44M 700.91M 597.49M 821.16M
Total Debt 451.49M 7.11M 6.17M 87.75M 324.39M
Cash & Equivalents 174.93M 72.31M 22.95M 45.01M 19.52M
Current Assets 832.27M 331.56M 237.43M 263.60M 464.75M
Current Liabilities 37.45M 37.11M 16.78M 98.81M 41.67M